Immunovant (IMVT) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $27.51, -1.40% vs the prior close of $27.90.
- Volume 1.65M shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IMVT dips 1.4% to $27.51, a 3-month low, 4 down days in a row. Closed at $27.51, -1.40% vs the prior close of $27.90. Day range $27.48–$28.33, opened at $28.03.
IMVT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — IMVT dips 1.4% to $27.51, a 3-month low, 4 down days in a row
- Closed at $27.51, -1.40% vs the prior close of $27.90. Day range $27.48–$28.33, opened at $28.03.
- Volume was 1.65M shares, 1.2x its 50-day average of 1.40M.
- Price is -26.8% vs its 50-day average ($37.56) and -13.8% vs its 200-day average ($31.90).
- 52-week range $17.02–$45.42; today's close sits at 37% of that range, 39.4% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — IMVT dips 2.8% to $27.90, a 3-month low, 3 down days in a row
- Closed at $27.90, -2.82% vs the prior close of $28.71. Day range $27.83–$28.79, opened at $28.46.
- Volume was 1.77M shares, 1.3x its 50-day average of 1.38M.
- Price is -26.2% vs its 50-day average ($37.79) and -12.5% vs its 200-day average ($31.89).
- 52-week range $16.77–$45.42; today's close sits at 39% of that range, 38.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — IMVT dips 2.6% to $28.71, a 3-month low
- Closed at $28.71, -2.61% vs the prior close of $29.48. Day range $28.70–$29.64, opened at $29.37.
- Volume was 1.24M shares, 0.9x its 50-day average of 1.37M.
- Price is -24.5% vs its 50-day average ($38.02) and -10.0% vs its 200-day average ($31.88).
- 52-week range $16.77–$45.42; today's close sits at 42% of that range, 36.8% below the 52-week high.
Oct 12, 2026 — IMVT slides 3.2% to $29.48, a 3-month low
- Closed at $29.48, -3.25% vs the prior close of $30.47. Day range $28.61–$30.59, opened at $30.17.
- Volume was 2.24M shares, 1.7x its 50-day average of 1.34M.
- Price is -22.9% vs its 50-day average ($38.22) and -7.5% vs its 200-day average ($31.87).
- 52-week range $16.59–$45.42; today's close sits at 45% of that range, 35.1% below the 52-week high.
Oct 9, 2026 — IMVT rises 0.7% to $30.47
- Closed at $30.47, +0.69% vs the prior close of $30.26. Day range $30.07–$30.64, opened at $30.25.
- Volume was 1.49M shares, 1.1x its 50-day average of 1.32M.
- Price is -20.7% vs its 50-day average ($38.40) and -4.4% vs its 200-day average ($31.86).
- 52-week range $16.08–$45.42; today's close sits at 49% of that range, 32.9% below the 52-week high.
Oct 8, 2026 — IMVT slides 5.6% to $30.26, a 3-month low, 6 down days in a row
- Closed at $30.26, -5.56% vs the prior close of $32.04. Day range $29.80–$31.50, opened at $31.40.
- Volume was 1.76M shares, 1.3x its 50-day average of 1.32M.
- Price is -21.6% vs its 50-day average ($38.58) and -5.0% vs its 200-day average ($31.85).
- 52-week range $16.04–$45.42; today's close sits at 48% of that range, 33.4% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — IMVT ends flat (-0.2%) to $32.04, a 3-month low, 5 down days in a row
- Closed at $32.04, -0.22% vs the prior close of $32.11. Day range $31.58–$32.75, opened at $31.72.
- Volume was 1.13M shares, 0.9x its 50-day average of 1.32M.
- Price is -17.3% vs its 50-day average ($38.75) and +0.7% vs its 200-day average ($31.83).
- 52-week range $15.95–$45.42; today's close sits at 55% of that range, 29.5% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — IMVT slides 3.4% to $32.11, a 3-month low, 4 down days in a row
- Closed at $32.11, -3.43% vs the prior close of $33.25. Day range $31.36–$33.51, opened at $33.51.
- Volume was 1.67M shares, 1.3x its 50-day average of 1.30M.
- Price is -17.4% vs its 50-day average ($38.88) and +1.0% vs its 200-day average ($31.80).
- 52-week range $15.95–$45.42; today's close sits at 55% of that range, 29.3% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — IMVT dips 1.1% to $33.25, a 3-month low, 3 down days in a row
- Closed at $33.25, -1.10% vs the prior close of $33.62. Day range $32.95–$33.99, opened at $33.99.
- Volume was 1.10M shares, 0.9x its 50-day average of 1.29M.
- Price is -14.8% vs its 50-day average ($39.04) and +4.6% vs its 200-day average ($31.77).
- 52-week range $15.95–$45.42; today's close sits at 59% of that range, 26.8% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — IMVT ends flat (-0.1%) to $33.62
- Closed at $33.62, -0.09% vs the prior close of $33.65. Day range $33.21–$34.24, opened at $34.11.
- Volume was 1.02M shares, 0.8x its 50-day average of 1.29M.
- Price is -14.2% vs its 50-day average ($39.17) and +5.9% vs its 200-day average ($31.74).
- 52-week range $15.95–$45.42; today's close sits at 60% of that range, 26.0% below the 52-week high.
IMVT latest news & SEC filings
Every SEC filing by or about IMVT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Stout Jay S sold 2,213 shares at $32.06 (≈$70.95K) on Oct 7, 2026; now holds 203,128
- Stout Jay S sold 1,596 shares at $32.06 (≈$51.17K) on Oct 7, 2026; now holds 201,532
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Van Tuyl Christopher sold 1,327 shares at $32.06 (≈$42.54K) on Oct 7, 2026; now holds 175,218
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gloria Melanie sold 2,241 shares at $32.06 (≈$71.85K) on Oct 7, 2026; now holds 217,060
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Venker Eric converted options/RSUs into 92,187 shares at $14.46 (≈$1.33M) on Oct 1, 2026; now holds 346,467
- Venker Eric returned to the company 85,886 shares at $33.65 (≈$2.89M) on Oct 1, 2026; now holds 260,581
- Venker Eric sold 3,506 shares at $34.11 (≈$119.59K) on Oct 2, 2026; now holds 257,075
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Van Tuyl Christopher sold 2,846 shares at $36.36 (≈$103.48K) on Sep 23, 2026; now holds 176,545
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Aug 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Pande Atul sold 1,500 shares at $43.27 (≈$64.91K) on Aug 28, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$153.22M (prior year -$120.61M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.75 (prior year -$0.71) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 22, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Jul 22, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Jul 22, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Things to know before you trade IMVT
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 20, 2026, Feb 6, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.85% (largest 7.4%).
- Liquidity: about 1.72M shares (≈$47.38M) trade per day on average.
- 52-week position: $27.51 vs a range of $17.02–$45.42 (37% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Tuyl Christopher Van sold 2,846 shares on Sep 23, 2026.
- Latest filings: 8-K Sep 3, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 206.55M shares outstanding (Aug 3, 2026), +18.5% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
IMVT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 28.03 | 28.33 | 27.48 | 27.51 | 1.65M |
| Oct 14, 2026 | 28.46 | 28.79 | 27.83 | 27.90 | 1.77M |
| Oct 13, 2026 | 29.37 | 29.64 | 28.70 | 28.71 | 1.24M |
| Oct 12, 2026 | 30.17 | 30.59 | 28.61 | 29.48 | 2.24M |
| Oct 9, 2026 | 30.25 | 30.64 | 30.07 | 30.47 | 1.49M |
| Oct 8, 2026 | 31.40 | 31.50 | 29.80 | 30.26 | 1.76M |
| Oct 7, 2026 | 31.72 | 32.75 | 31.58 | 32.04 | 1.13M |
| Oct 6, 2026 | 33.51 | 33.51 | 31.36 | 32.11 | 1.67M |
| Oct 5, 2026 | 33.99 | 33.99 | 32.95 | 33.25 | 1.10M |
| Oct 2, 2026 | 34.11 | 34.24 | 33.21 | 33.62 | 1.02M |
| Oct 1, 2026 | 33.56 | 34.60 | 33.30 | 33.65 | 1.67M |
| Sep 30, 2026 | 33.62 | 34.19 | 33.12 | 33.78 | 1.43M |
| Sep 29, 2026 | 33.43 | 33.53 | 32.45 | 33.46 | 1.31M |
| Sep 28, 2026 | 32.93 | 33.77 | 32.65 | 33.49 | 1.23M |
| Sep 25, 2026 | 34.00 | 34.22 | 33.17 | 33.30 | 2.35M |
| Sep 24, 2026 | 34.21 | 34.54 | 33.35 | 34.00 | 1.48M |
| Sep 23, 2026 | 36.35 | 37.00 | 33.60 | 34.54 | 3.65M |
| Sep 22, 2026 | 37.38 | 38.15 | 36.84 | 37.29 | 2.26M |
| Sep 21, 2026 | 37.23 | 37.49 | 36.55 | 37.18 | 1.03M |
| Sep 18, 2026 | 37.52 | 38.35 | 36.80 | 36.95 | 2.94M |
About Immunovant
Immunovant (IMVT) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in DURHAM, NC. State of incorporation: DE. Fiscal year ends March 31. SEC CIK 1764013.
IMVT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jake Bauer | Director | Apr 9, 2026 |
| Andrew J. Fromkin | Director | May 29, 2026 |
| Douglas J. Hughes | Director | Apr 9, 2026 |
| Atul Pande | Director | Aug 28, 2026 |
| Sciences Ltd. Roivant | Director | Dec 12, 2025 |
| Robert Graham Susman | Director | May 1, 2026 |
| Frank Torti | Director | Apr 9, 2026 |
| Eric Venker | Chief Executive Officer | Jul 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michael Geffner | Chief Medical Officer | Oct 24, 2025 |
| Tiago Girao | Chief Financial Officer | Jul 24, 2026 |
| Melanie Gloria | Chief Operating Officer | Aug 21, 2026 |
| Jay S Stout | Chief Technology Officer | Jul 24, 2026 |
| Tuyl Christopher Van | Chief Legal Officer | Sep 25, 2026 |
| Eric Venker | Chief Executive Officer | Jul 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 23, 2026 | Tuyl Christopher Van | Sale | 2,846 | $36.36 |
| Aug 28, 2026 | Atul Pande | Sale | 1,500 | $43.27 |
| Aug 20, 2026 | Melanie Gloria | Sale | 3,056 | $44.16 |
| Jul 24, 2026 | Atul Pande | Sale | 1,500 | $39.80 |
| Jul 23, 2026 | Jay S Stout | Sale | 2,857 | $38.69 |
| Jul 23, 2026 | Tiago Girao | Sale | 6,798 | $38.69 |
| Jul 8, 2026 | Melanie Gloria | Sale | 106 | $39.99 |
| Jul 8, 2026 | Melanie Gloria | Sale | 1,930 | $39.53 |
| Jul 8, 2026 | Tuyl Christopher Van | Sale | 63 | $39.99 |
| Jul 8, 2026 | Tuyl Christopher Van | Sale | 1,143 | $39.53 |
| Jul 8, 2026 | Jay S Stout | Sale | 1,399 | $39.53 |
| Jul 8, 2026 | Jay S Stout | Sale | 77 | $39.99 |
| Jul 8, 2026 | Jay S Stout | Sale | 105 | $39.99 |
| Jul 8, 2026 | Jay S Stout | Sale | 1,906 | $39.53 |
| Jul 2, 2026 | Eric Venker | Sale | 3,092 | $38.48 |
IMVT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Mar 31, 2026 | — | $-505.61M | -2.77 | $-407.31M |
| Mar 31, 2025 | — | $-413.84M | -2.73 | $-375.87M |
| Mar 31, 2024 | — | $-259.34M | -1.88 | $-214.23M |
| Mar 31, 2023 | — | $-210.96M | -1.71 | $-188.19M |
| Mar 31, 2022 | — | $-156.73M | -1.43 | $-106.11M |
Latest balance sheet: total assets $852.49M, total liabilities $117.10M, cash $797.80M (as of Jun 30, 2026).
IMVT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $39.74 |
| May 20, 2026 | 8-K Item 2.02 (results) | $35.56 |
| Feb 6, 2026 | 8-K Item 2.02 (results) | $27.05 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $23.37 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $14.76 |
| May 29, 2025 | 8-K Item 2.02 (results) | $14.89 |
| Feb 6, 2025 | 8-K Item 2.02 (results) | $20.36 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $29.93 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 29, 2024 | 8-K Item 2.02 (results) | — |
| Feb 12, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on IMVT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.